Next Article in Journal
Synthesis and Antiplasmodial Activity of 3-Furyl and 3-Thienylquinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives
Next Article in Special Issue
Synthesis and Structural Analysis of Polyester Prodrugs of Norfloxacin
Previous Article in Journal
A New Phenolic Amide from the Roots of Paris verticillata
Previous Article in Special Issue
Efficacy of DA-7218, a New Oxazolidinone Prodrug, in the Treatment of Experimental Actinomycetoma Produced by Nocardia brasiliensis
Article Menu

Export Article

Open AccessReview
Molecules 2008, 13(1), 46-68; doi:10.3390/molecules13010046

Antiparkinson Prodrugs

Department of Drug Sciences, “G. d'Annunzio” University, School of Pharmacy, Via dei Vestini 31, 66100 Chieti, Italy
Author to whom correspondence should be addressed.
Received: 4 December 2007 / Revised: 11 January 2008 / Accepted: 11 January 2008 / Published: 16 January 2008
(This article belongs to the Special Issue Prodrugs)


Parkinson`s disease (PD) is a progressive, neurodegenerative disorder whichinvolves the loss of dopaminergic neurons of the substantia nigra pars compacta. Currenttherapy is essentially symptomatic, and L-Dopa (LD), the direct precursor of dopamine(DA), is the treatment of choice in more advanced stages of the disease. Substitutiontherapy with LD is, however, associated with a number of acute problems. The peripheralconversion of LD by amino acid decarboxylase (AADC) to DA is responsible for thetypical gastrointestinal (nausea, emesis) and cardiovascular (arrhythmia, hypotension) sideeffects. To minimize the conversion to DA outside the central nervous system (CNS) LD isusually given in combination with peripheral inhibitors of AADC (carbidopa andbenserazide). In spite of that, other central nervous side effects such as dyskinesia, on-offphenomenon and end-of-dose deterioration still remain. The main factors responsible forthe poor bioavailability and the wide range of inter- and intra-patient variations of plasmalevels are the drug’s physical-chemical properties: low water and lipid solubility, resultingin unfavourable partition, and the high susceptibility to chemical and enzymaticdegradation. In order to improve the bioavailability, the prodrug approach appeared to bethe most promising and some LD prodrugs have been prepared in an effort to solve theseproblems. We report here a review of progress in antiparkinson prodrugs, focusing onchemical structures mainly related to LD, DA and dopaminergic agonists.
Keywords: L-dopa; Dopamine; Prodrugs; antiparkinson L-dopa; Dopamine; Prodrugs; antiparkinson
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Di Stefano, A.; Sozio, P.; Cerasa, L.S. Antiparkinson Prodrugs. Molecules 2008, 13, 46-68.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top